• Grazoprevir/Elbasvir: Advances in HCV Genotype 1 and 4 Thera

  2026-08-06

  The reference study by Vallet-Pichard and Pol provides a comprehensive analysis of the fixed-dose combination of grazoprevir (MK-5172 hydrate) and elbasvir for hepatitis C virus (HCV) infection. Their review highlights this regimen’s high efficacy, tolerability, and applicability across challenging patient populations, marking a significant advance over previous interferon-based protocols.

• HLY78: Applied Wnt/β-Catenin Pathway Modulator in Research

  2026-08-05

  HLY78 delivers precision control over Wnt/β-catenin signaling, enabling robust model development in embryogenesis and fibrosis research. Its Axin-targeted mechanism outperforms traditional activators, unlocking reproducible stem cell marker induction and nuanced pathway interrogation.

• ICG001: Wnt/β-Catenin Pathway Inhibitor for Translational Wo

  2026-08-05

  ICG001 stands apart as a precise modulator of Wnt/β-catenin signaling, enabling targeted investigation of CBP/β-catenin associations in cancer, fibrosis, and regenerative models. This guide details robust experimental workflows, troubleshooting strategies, and actionable insights to maximize reproducibility across diverse biological systems.

• AMPK Modulates M1 Macrophage Polarization in Obesity-Related

  2026-08-04

  This study uncovers how AMPK activity regulates M1 macrophage polarization via the JAK2/STAT3 pathway, attenuating airway inflammation in obesity-related asthma. The findings advance mechanistic understanding and highlight novel intervention points for targeting metabolic-inflammation in refractory asthma phenotypes.

• Dorsomorphin (Compound C): Precision for AMPK and BMP Pathwa

  2026-08-04

  Dorsomorphin (Compound C) empowers researchers to dissect AMPK and BMP signaling with high selectivity, enabling robust exploration of metabolic, autophagy, and differentiation pathways. This article details actionable workflows, troubleshooting strategies, and practical insights for maximizing assay reproducibility with APExBIO’s Dorsomorphin.

• IGF2BP2 Inhibition Disrupts Glycolysis and Cell Cycle in Ova

  2026-08-03

  This study identifies IGF2BP2, an m6A reader, as a key driver of glycolysis and cell proliferation in ovarian cancer by stabilizing oncogenic mRNAs. IGF2BP2 inhibition—either genetically or pharmacologically—impairs metabolic and survival pathways, highlighting a promising therapeutic target for precision oncology.

• Advanced In Vitro Methods to Quantify Cancer Drug Responses

  2026-08-03

  Schwartz (2022) introduces a rigorous comparison of in vitro drug response metrics in cancer research, clarifying the distinction between proliferative arrest and cell death induced by anticancer compounds. This work informs the optimization of preclinical drug evaluation workflows and highlights the importance of nuanced assay design for translational oncology.

• SU6656 Src Tyrosine Kinases Inhibitor in Platelet & Cancer R

  2026-08-02

  SU6656 Src tyrosine kinases inhibitor is transforming both ex vivo platelet production and radiotherapy enhancement workflows. This article delivers actionable protocol guidance, real-world troubleshooting, and data-backed comparisons to help researchers unlock the full translational power of SU6656 in stem cell and oncology settings.

• Fenofibrate as a PPARα Agonist: Quantitative Insights & Rese

  2026-08-01

  Explore Fenofibrate's unique potency as a PPARα agonist, with in-depth analysis of its quantitative impact on PPARα-YAP signaling and liver modeling. This cornerstone guide offers advanced protocol guidance, mechanistic clarity, and decision-making insight for lipid metabolism and cancer biology research.

• Capsaicin (E)-Capsaicin: Precision Modulation of TRPV1 for N

  2026-07-31

  Explore how Capsaicin (E)-Capsaicin enables precise, mechanism-driven modulation of TRPV1 ion channels and epigenetic targets in advanced neuropathic pain models. This article uncovers new assay insights and translational applications beyond established paradigms.

• Dorsomorphin (Compound C): Precision Modulation of AMPK and

  2026-07-31

  Explore the multifaceted roles of Dorsomorphin (Compound C) in AMPK and BMP pathway inhibition, with new insights into autophagy and muscle metabolism. This article uniquely connects recent mitophagy research with advanced protocol guidance for Dorsomorphin users.

• 5X Protein Loading Buffer (Reducing): Technical Use in SDS-P

  2026-07-30

  5X Protein Loading Buffer (Reducing) provides robust protein denaturation and disulfide bond reduction for SDS-PAGE workflows where accurate molecular weight separation is required. It should not be used in protocols that require preservation of native protein structure or non-reducing conditions. This article covers technical use, setup, and troubleshooting.

• Human SAN-Plexus Assembloids Model Neuro-Cardiac Pacemaker M

  2026-07-30

  This study introduces a human pluripotent stem cell-derived assembloid platform integrating sinoatrial node and cardiac plexus organoids, enabling functional analysis of neuro-cardiac interactions during pacemaker maturation. The model advances mechanistic understanding of neuron-to-pacemaker signaling and offers a new resource for studying conduction diseases.

• Pharmacokinetic Variability of CSBTA in MASH: Mechanisms and

  2026-07-29

  This study systematically dissects how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. By integrating transporter and enzyme expression profiles, the research provides actionable insights for optimizing preclinical models and dosing strategies relevant to metabolic liver disease.

• PORCN Inhibition with LGK-974 as a Therapeutic Avenue for Sc

  2026-07-29

  The referenced study demonstrates that pharmacological inhibition of Porcupine (PORCN) using LGK-974 can reduce excessive bone formation in sclerosteosis, a rare high bone mass disorder caused by SOST mutations. This work provides the first preclinical evidence for targeting Wnt signaling with a PORCN inhibitor to address severe skeletal overgrowth, offering a potential alternative to high-risk surgical interventions.

15830 records 2/1056 page Previous Next 12345 下5页 Last page